Alpha-fetoprotein and des-gamma-carboxy-prothrombin at twenty-four weeks after interferon-based therapy predict hepatocellular carcinoma development

doi:10.4254/wjh.v7.i27.2757

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 7, Issue 27

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9137)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-5) series, Tables (1-4) series.

Item

Count

PDF

646

WORD

411

HTML

4083

Figures (1-5)

259

Tables (1-4)

222

Sum=5621

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1348

Download

2168

Sum=3516

Nov 28, 2015 (publication date) through Dec 28, 2024

Times Cited of This Article

Times Cited (4)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Hepatol. Nov 28, 2015; 7(27): 2757-2764
Published online Nov 28, 2015. doi: 10.4254/wjh.v7.i27.2757

Full Size Figure Download Figure

Figure 4 Cumulative incidence of hepatocellular carcinoma according to alpha-fetoprotein levels. ¹The value at 24 wk after the completion of interferon-based therapy (ng/mL). AFP: Alpha-fetoprotein; HCC: Hepatocellular carcinoma.

Citation: Shakado S, Sakisaka S, Chayama K, Okanoue T, Toyoda J, Izumi N, Matsumoto A, Takehara T, Ido A, Hiasa Y, Yoshioka K, Nomura H, Ueno Y, Seike M, Kumada H. Alpha-fetoprotein and des-gamma-carboxy-prothrombin at twenty-four weeks after interferon-based therapy predict hepatocellular carcinoma development. World J Hepatol 2015; 7(27): 2757-2764
URL: https://www.wjgnet.com/1948-5182/full/v7/i27/2757.htm
DOI: https://dx.doi.org/10.4254/wjh.v7.i27.2757